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SUMMARY
Early and loco-regionally advanced oral tongue squamous cell carcinoma (OTSCC) can be treated by surgery alone or followed by adjuvant radio-
therapy or chemoradiotherapy. Nevertheless, up to 40% of patients develop tumour relapse. The aim of our study is to investigate the clinical and 
pathological features associated with reduced disease-free survival (DFS) in a cohort of surgically-resected OTSCC patients. One hundred and six 
patients surgically resected for OTSCC were retrospectively identified from clinical records. DFS was calculated according to the Kaplan–Meier 
method and differences between variables were assessed with Log-Rank test. A multivariable Cox regression model was used to analyse the impact 
of different prognostic factors on DFS. After a median of follow-up of 8.9 years, 22 events, including 11 deaths, were observed. Overall, the 5-year 
DFS-rate was 87.4%. The presence of extra-nodal extension (p = 0.023) and perineural invasion (p = 0.003) were significantly correlated with 
shorter DFS (in univariate analysis). In multivariable analysis, extra-nodal extension and perineural invasion confirmed their role as independent 
prognostic factors associated with an increased risk of disease recurrence [hazard ratio (HR) 2.87, 95% CI 1.11 - 7.42, p = 0.03; HR 3.85, 95% CI 
1.49 - 9.96, p = 0.006, respectively]. p16 and p53 expressions in tumour cells were detected in 12% (n = 9) and 46% (n = 40) of cases, respectively. 
No differences in DFS were observed between p16+ and p16- (p = 0.125) and between p53+ and p53- tumours (p = 0.213). In conclusion, radical 
surgery, eventually followed by adjuvant radiotherapy or chemo-radiotherapy, can achieve high cure rates in OTSCC. After long-term follow-up, 
perineural invasion and extra-nodal extension confirmed their role as prognostic factors associated with reduced DFS in OTSCC patients. 
KEY WORDS: Oral cancer • Tongue cancer • Head and neck squamous cell carcinoma • p53 • p16
RIASSUNTO 
Il tumore della lingua mobile, in fase iniziale o localmente avanzata, può essere trattato mediante chirurgia, da sola o seguita da radio-
terapia o chemio-radioterapia. Tuttavia, fino al 40% dei pazienti sviluppa una recidiva di malattia. Lo scopo del nostro studio è quello 
di valutare le caratteristiche anatomo-patologiche e cliniche associate ad una ridotta sopravvivenza libera da malattia (DFS) in pazienti 
con tumore della lingua mobile sottoposti a chirurgia. Sono stati identificati 106 pazienti operati per tumore della lingua mobile. Dopo un 
follow-up mediano di 8,9 anni, sono stati osservati 22 eventi, incluse 11 morti. Il tasso di DFS a 5 anni è stato dell’87,4%. La presenza di 
estensione extranodale (p = 0,023) ed invasione perineurale (p = 0,003) erano significativamente correlate ad una DFS ridotta (analisi 
univariata). Nell’analisi multivariata, sia l’estensione extranodale che l’invasione perineurale hanno confermato il loro ruolo quali fattori 
prognostici associati ad un aumentato rischio di recidiva di malattia [Hazard Ratio (HR) 2,87, 95% CI 1,11 - 7,42, p = 0,03; HR 3,85, 
95% CI 1,49 - 9,96, p = 0,006]. L’espressione di p16 e p53 è stata identificata nel 12% (n = 9) e 46% (n = 40) dei casi, rispettivamente. 
Non sono state identificate differenze in termini di sopravvivenza tra tumori p53+ e p53-, né tra tumori p16+ e p16-. In conclusione, la 
chirurgia primaria, eventualmente seguita da radioterapia o chemio-radioterapia, può consentire alti livelli di guarigione nel tumore della 
lingua mobile. L’invasione perineurale e l’estensione extra-nodale si sono confermati fattori prognostici correlati ad una minore DFS. 
PAROLE CHIAVE: Tumori del cavo orale • Tumore della lingua • Tumori della testa e del collo • p53 • p16
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Introduction
Oral tongue squamous cell carcinoma (OTSCC) is the 
most common cancer diagnosed in the oral cavity, ac-
counting for 25-40% of all oral malignancies  1. In the 
United States, almost 17,000 new cases and 2,500 
OTSCC-related deaths are expected in 2018 2. OTSCC is 
burdened by significant morbidity and mortality and its 
incidence is continuously arising, particularly in young 
subjects 3 4. Despite advances in detection and treatment, 
5-year overall survival (OS) and disease-free survival 
(DFS) are steadily in the range of 50-60% 1 5. The patho-
genesis of OTSCC is related to several factors involved 
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in the carcinogenetic process such as heat, chronic in-
juries, poor oral hygiene, cigarette smoking and alcohol 
consumption  6. Moreover, OTSCC is characterised by a 
high frequency of lymphatic metastasis, a high risk of re-
currence and the possibility to develop drug resistance to 
chemotherapy during treatment 7. 
Clinical outcomes strictly correlate with disease stage and 
lymph node spread at the time of presentation. Moreover, 
some characteristics, such as tumour depth, vascular and 
perineural invasion (PNI) and tumour budding are widely 
recognised as prognostic factors 8-13. Conversely, the im-
pact on survival of other features, including anatomic site, 
age, tumour grade and some biological markers is still un-
certain, depending on the great variability among reports 
in the literature, which is mainly represented by limited 
case series 14 15. A further confusing factor is the evalua-
tion of oral tongue cancers either in series including base 
of tongue tumours or in series reporting a combination of 
cancers from different sites in the head and neck district. 
The management and outcomes of each subsite tend to be 
different 16 17. 
Surgery is the standard treatment for early OTSCC. Lo-
cally and loco-regionally advanced cases can be treated 
by surgery and adjuvant radiotherapy (RT) or chemora-
diotherapy (CRT) according to the presence of risk factors 
such as lymph node metastases, extra-nodal extension 
(ENE) and involved surgical margins  18 19. Alternatively, 
primary concomitant CRT can be offered to patients with 
the aim of sparing organ function.
In this study, we retrospectively evaluated the role of sur-
gery on clinical outcomes in a cohort of patients affected 
by OTSCC treated at our institution in the last decade.
Materials and methods
Study setting
This was a monocentric, retrospective, independent study 
on patients with surgically-resected OTSCC treated and 
followed at San Paolo Hospital (Milan, Italy) between 
July 2004 and December 2012. Demographic data, risk 
factors, tumour characteristics and disease status were ob-
tained from medical records. The study was approved by 
local Ethics Committee. All patients alive at the time of 
data collection and/or analysis signed an informed con-
sent for use of personal data. 
All pathological specimens were reviewed by two inde-
pendent pathologists to confirm diagnosis and evaluate 
tumour depth, grade of tumour cell differentiation, pres-
ence of perivascular invasion and PNI, marginal status 
and the presence of ENE. Tumour size and nodal involve-
ment were categorised according to the American Joint 
Committee on Cancer (AJCC) TNM staging (7th Edition, 
2009). 
All cases were previously discussed and evaluated by a 
multidisciplinary team, consisting minimally of an oncol-
ogist, surgeon, radiotherapist, and dedicated radiologists 
and pathologists. Patients with localised or loco-regional 
disease were treated by radical surgery, consisting of tu-
mour resection +/- lymph node neck dissection. The de-
cision to proceed with lymph node neck dissection was 
taken after careful evaluation of nodal involvement at 
baseline imaging or as a consequence of pathological di-
agnosis. Patients with a tumour depth greater than 3 mm 
were deferred to elective neck dissection 20. Patients with 
positive or close surgical margins, defined as the presence 
of tumour cells at the margin or within 5 mm, received 
surgical re-intervention (whenever possible) or RT/CRT. 
Patients at risk of relapse (node metastases, ENE, critical 
margins) were treated with adjuvant RT or CRT, accord-
ing to national and international guidelines 18 21. 
Patients were then referred to the Oncology Unit for fol-
low-up. Each follow-up visit included physical examina-
tion, blood tests and CT scan or MRI of the head and neck 
region (every 3 months during the first 2 years, and then 
every 6 to 12 months). 
Study population 
Eligibility criteria were: (1) age ≥18 years; (2) pathologi-
cally confirmed diagnosis of resected OTSCC; (3) ECOG 
performance status (PS) of 0-2; (4) available data on risk 
factors, tumour characteristics and patient outcomes. Pa-
tients with (1) distant metastases at baseline imaging and/
or (2) primary tumour of the tongue base or other sites of 
the head and neck district were not included in the study. 
Objectives
The main objective of the study was to investigate the im-
pact of clinical and pathological characteristics on surviv-
al of patients with completely resected OTSCC. The pri-
mary endpoint was disease-free survival (DFS), defined 
as the time from surgery until the date of relapse, date of 
death or last follow-up visit, whichever occurred first. The 
secondary endpoint was overall survival (OS), defined as 
the time from surgery until the date of death.
Immunohistochemistry for p16 and p53 
Immunohistochemistry (IHC) was performed according 
to standard protocols at our institution. Formalin-fixed, 
paraffin-embedded tissue sections (4 mm) from OTSCC 
tumour samples were used as substrates in IHC reactions. 
IHC staining with monoclonal antibodies (mAbs) labeled 
for p16INK4A (clone E6H4, Dako, Glostrup, Denmark) and 
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p53 (clone DO-7, Thermo Fisher Scientific, MA, US) was 
performed, as previously described  22  23. Tumour slides 
were evaluated and classified by two pathologists. Posi-
tive p16 and p53 expressions were defined as the presence 
of strong and diffuse nuclear and cytoplasmic staining in 
more than 70% of tumour cells. 
Statistical analysis
Demographic and clinical-pathological features were 
analysed using descriptive statistics. Absolute frequency 
and percentage were used to describe categorical vari-
ables, while median and interquartile range were reported 
for continuous variables. DFS was estimated using the 
Kaplan-Meier method and differences between variables 
were assessed with the Log-Rank test (univariate analy-
sis). Cox proportional hazard regression models were 
used to evaluate the association between demographic and 
clinical-pathological variables and the survival endpoint. 
Statistical tests were two-sided and p-value less than 0.05 
was considered as statistically significant. All the analyses 
were performed using SAS software v. 9.4 (SAS Institute, 
Cary, NC, US).
Results
Between July 2004 and December 2012, 106 OTSCC pa-
tients were included in the study. Patient characteristics 
are summarised in Table I. 
Median age was 61 years (interquartile range  =  51-69). 
Sixty-eight patients (64.1%) were male. Most patients 
presented with pT1 and pT2 disease (n = 56, 52.8%, and 
n = 31, 29.2%, respectively), while only a minority with 
pT3 and pT4 disease (n = 5, 4.7%, and n = 14, 13.2%, re-
spectively). A tumour depth greater than 3 mm was found 
in 74 cases (69.8%). Nodal involvement was detected in 
37 patients (34.9%), with the presence of ENE in 16 tu-
mours (15.1%). Tumours were well/moderately or poorly 
differentiated in 83 (78.3%) and 23 (21.7%) cases, respec-
tively. PNI and perivascular invasions were detected in 13 
(12.2%) and 9 (8.4%) tumours, respectively. Close or pos-
itive surgical margins were present in 17 (16.0%) cases. 
Overall, 63 patients (59.4%) were diagnosed with stage 
I or II disease, while stages III and IV were present in 
14 (13.2%) and 29 (27.4%) cases, respectively. Regarding 
neck management, 82 patients (77.3%) underwent neck 
dissection, concomitant to or deferred with respect to 
radical surgery. Sixty patients did not receive any postop-
erative treatment. Conversely, 27 (25.5%) and 19 (17.9%) 
patients received postoperative RTX or CRT, respectively, 
according to the presence of risk factors as previously de-
scribed.
Table I. Baseline characteristics (N = 106).
N %
Age
Median (IQR) 61 (51-69)
< 40 years 14 13.2
≥ 40 years 92 86.8
Sex
Male 68 64.1
Female 38 35.9
Smoker
No 31 29.2
Yes 75 70.8
Neck dissection
No 24 22.6
Yes 82 77.4
Tumour
pT1/2 87 82.1
pT3/4 19 17.9
pT1 56 52.8
pT2 31 29.2
pT3 5 4.7
pT4 14 13.2
Node
pN0/X 69 65.1
pN1/2/3 37 34.9
pNX 25 23.6
pN0 44 41.5
pN1 13 12.3
pN2 23 21.7
pN3 1 0.9
Stage
I/II 63 59.4
III/IV 43 40.6
I 46 43.4
II 17 16.0
III 14 13.2
IV 29 27.4
ENE
Missing 3 2.8
No 87 82.1
Yes 16 15.1
Depth
< 3 mm 32 30.2
≥ 3 mm 74 69.8
Vascular invasion
Missing 3 2.8
No 94 88.7
Yes 9 8.5
ucontinues
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To evaluate any difference between age and clinical-
pathological features, patients were subdivided into 2 age 
groups: <40 and ≥40 years (n = 14, 13.21% and n = 92, 
86.79%, respectively). No significant differences in terms 
of tumour characteristics were observed between the two 
groups.
Survival analysis
Three patients were excluded from survival analysis due 
to the lack of information about the time of disease pro-
gression and/or death. 
After a median of follow-up of 8.9 years (5.3 - 11.4), 22 
(21.4%) events occurred, including 11 (10.7%) deaths 
(Table II). 
In the first five years of follow-up, 13 tumour relapses, 
including 11 deaths, were observed. The 5-year DFS and 
OS rates were 87.4% and 91.3%, respectively.
Using log-rank test, no significant differences in terms of 
DFS were observed for age groups (p = 0.222), smoking 
status (p = 0.193), tumour size (p = 0.407), nodal involve-
ment (p = 0.379), tumour depth (p = 0.161), vascular in-
vasion (p = 0.291), tumour differentiation (p = 0.062) and 
surgical margins (p = 0.064). Conversely, the presence of 
ENE (p = 0.023) and PNI (p = 0.003) were significantly 
correlated with shorter DFS (Fig. 1). 
In multivariable Cox regression analysis, the pres-
ence of ENE [Hazard Ratio (HR) 2.87, 95% CI 1.11 - 
7.42, p = 0.03] and PNI (HR 3.85, 95% CI 1.49 - 9.96, 
p = 0.006) were significantly associated with a higher risk 
of disease recurrence (Table III).
Regarding OS, in the multivariable Cox regression analy-
sis, no significant differences were detected for age groups 
(p = 0.837), smoking status (p = 0.526), PNI (p = 0.178), 
ENE (p = 0.961), nodal involvement (p = 0.553), tumour 
depth (p = 0.515), tumour size (P = 0.751), vascular inva-
sion (p = 0.753), tumour differentiation (p = 0.087) and 
surgical margins (p = 0.702).
Analysis for p16 and p53 expressions
Of the 106 tumours examined, 75 tissue samples were 
available for evaluation of p16 and p53 expression, which 
was present in 12% (n = 9) and 46% (n = 40) of the sam-
ples, respectively. However, no significant correlations 
with clinical features were observed.
In univariate analysis, no differences in terms of DFS and 
OS were observed between p16+ and p16- (p = 0.125), as 
well as between p53+ and p53- tumours (p = 0.213). 
Discussion 
Radical surgery, eventually followed by RT or CRT, is the 
standard treatment for OTSCC leading to about a 70% 
probability of cure in the early stages 18. Loco-regionally 
advanced disease still has a dismal prognosis and less than 
half of patients have a real chance of cure 24. An integrat-
ed approach consisting of multimodality diagnostic and 
therapeutic workup is mandatory for high risk patients, 
defined by the presence of aggressive features such as ad-
vanced primary tumour (T3 or T4), number and sites of 
N %
Perineural invasion
Missing 3 2.8
No 90 84.9
Yes 13 12.3
Tumour differentiation
G1/2 83 78.3
G3 23 21.7
Margins
No 89 84.0
Yes 17 16.0
Postoperative treatment
None 60 56.6
RT 27 25.5
CRT 19 17.9
CRT: chemo-radiotherapy ENE: extra-nodal extension; IQR: interquartile range; RT: 
radiotherapy.
Table I. follows.
Table II. DFS and OS events according to different stages of disease.
Stage DFS events OS events
No
N (%)
Yes
N (%)
No
N (%)
Yes
N (%)
I 35 (33.9) 10 (9.7) 42 (40.8) 3 (2.9)
II 15 (14.6) 2 (1.9) 16 (15.5) 1 (0.9)
III 11 (10.7) 1 (0.9) 12 (11.6) 0 (0.0)
IV 20 (19.4) 9 (8.7) 22 (21.4) 7 (6.9)
Total 81 (78.6) 22 (21.4) 92 (89.3) 11 (10.7)
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lymph node involvement, ENE, PNI, vascular infiltration, 
poor tumour differentiation and incomplete surgery  8-13. 
Although many studies have evaluated the role of multi-
modality treatment in head and neck cancers, only a few 
have focused on the impact of surgery and (chemo)radia-
tion in tongue cancer exclusively. 
We retrospectively analysed 106 OTSCC patients to iden-
tify risk factors associated with a reduced survival. The 
features of our population are in line with data available 
in the literature. Most of our patients had small tumours 
(especially pT1 and pT2), but nodal involvement was de-
tected in about one-third of cases. 
To detect differences in clinical-pathological features of dis-
ease presentation and recurrence, we subdivided the popula-
tion in two cohorts in relation to age (< 40 and ≥ 40 years). 
However, we found no difference between the two age 
groups. In the 14 patients in the youngest group, only one 
subject had disease recurrence in the observation period. 
We are aware that this could be related to the low percent-
age of young subjects in our population, nonetheless young 
age seems to consistently correlate with improved prog-
nosis. Regarding survival differences between young and 
older OTSCC patients, contrasting data have been provided 
so far. Some authors reported that young subjects present 
worse survival outcomes than the elderly, justifying more 
intensive treatments in this subgroup 25-28. Conversely, other 
studies demonstrated the absence of difference in terms 
of higher risk of disease recurrence or worse survival in 
young (< 40 years) OTSCC patients 29. On the other hand, 
some authors have highlighted the role of aging in poor 
prognosis 30 and the negative impact of comorbidities on 
elderly patients in terms of OS and postsurgical compli-
Fig. 1. Disease-free survival (DFS) in the overall population (a), and according to age (b), perineural invasion (c) and extracapsular extension (d).
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cations 31. However, these latter studies were not focused 
on OTSCC, but included patients with tumours at differ-
ent head and neck sites. Therefore, the impact of age on 
OTSCC prognosis has not been well defined and further 
studies that address this issue are warranted. 
In our population, 5-year DFS and OS rates were 87.4% 
and 91.3%, respectively. These encouraging survival 
outcomes could be attributed to the post-operative strat-
egies adopted, such as neck dissection and RT or CRT 
for patients displaying major risk factors. As previously 
described, patients with tumour depth greater than 3 mm 
were referred to elective neck dissection 20 as well as those 
with positive surgical margins, who received surgical re-
intervention or, if technically not feasible, adjuvant CRT. 
In addition, the presence of ENE was a further absolute 
indication to adjuvant CRT. Patients with minor risk fac-
tors such as pT3 or pT4 primary, N2 or N3 nodal disease, 
nodal disease in levels IV or V, PNI, vascular embolism or 
lymphatic invasion underwent adjuvant RTX 18 21. We did 
not find any difference in terms of DFS when considering 
smoking status, tumour size, nodal involvement, tumour 
depth, vascular invasion, positive surgical margins and 
cell differentiation. 
Moreover, our study did not demonstrate a link between 
p16 expression and survival, confirming that the prog-
nostic role of human papilloma virus (HPV) infection in 
OTSCC is not yet clear 32 33. In addition, p53 expression 
did not impact on survival. Thus, our study is in good 
Table III. Cox regression analysis for disease-free survival (DFS). 
N Events/PY HR 95% CI P-value
Age
 < 40 years 14 1/106
3.26 0.44-24.23 0.25
 ≥ 40 years 92 21/625
Smoker
 No 31 4/240
2.03 0.69-5.99 0.20
 Yes 75 18/491
pT
 pT1/2 87 17/620
1.52 0.56-4.13 0.41
 pT3/4 19 5/112
pN
 pN0/X 69 13/498
1.46 0.62-3.42 0.38
 pN1/2/3 37 9/234
ENE*
 No 87 15/625
2.87 1.11-7.42 0.03
 Yes 16 6/86
Depth
 < 3 32 4/245
2.13 0.72-6.30 0.17
 ≥ 3 74 18/487
Vascular invasion*
 No 94 18/657
1.91 0.56-6.50 0.30
 Yes 9 3/54
Perineural invasion*
 No 90 15/652
3.85 1.49-9.96 0.006
 Yes 13 6/59
Grading
 G1/2 83 14/591
2.24 0.94-5.34 0.07
 G3 23 8/141
Margins
 No 89 16/645
2.38 0.93-6.11 0.07
 Yes 17 6/86
* 3 patients with missing information. CI: confidence interval; HR: hazard ratio; ENE: extra-nodal extension; PY: per-year.
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agreement with the recent meta-analysis by Almangush et 
al., suggesting that p16 and p53 expression have no role 
as prognostic factors in OTSCC  34, while their pathoge-
netic role is unanimously recognised in oropharyngeal 
cancer  35  36. To date, no clear prognostic biomarker has 
been established for OTSCC patients treated with radi-
cal surgery. Ongoing research on new biomarkers and 
genomic determinants might allow better understanding 
of the factors involved in OTSCC pathogenesis and pro-
gression 37 38.
Notably, tumours presenting with PNI had a higher risk of 
disease recurrence. PNI has a well-recognised prognostic 
role and is associated with dismal prognosis in head and 
neck tumours 39 40. The presence of ENE also indicates an 
increased risk of tumour relapse, confirming its role as an 
independent poor prognostic factor 41.
Nowadays, high-quality surgery, eventually followed by 
RTX or CRT according to the presence of risk factors, 
represents the cornerstone on which long survival of early 
stage OTSCC is based. As previously described, in our 
population tumours with PNI and ENE presented a higher 
risk of disease relapse, underlining their significant role 
as prognostic factors. Moreover, their presence in tissue 
samples highlights the need of a careful multidisciplinary 
evaluation in order to plan the best postoperative thera-
peutic strategies. 
Conclusions
Our study, with the limitation of a retrospective analy-
sis, highlights the possibility to achieve high cure rates 
in OTSCC. PNI and ENE were independently associated 
with reduced DFS in our population. Survival rates of 
around 90% can be achieved by strict cooperation of a 
multidisciplinary team of experts that manages the patient 
from the first diagnostic approach to completion of treat-
ment and definition of proper follow-up.
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